ArticleFrontiers in bioengineering and biotechnology2024
Injectable MXene/Ag-HA composite hydrogel for enhanced alveolar bone healing and mechanistic study.
Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Enhancing Bone Repair Process: Application and Perspective on Photothermal Materials.Molecules (Basel, Switzerland) · 2026Review
- Cascade-Responsive MXene@Cu-MOF Heterostructure Integrates Antioxidant Activity, Infection Control, and Vascularization for Tracheal Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Injectable hydrogels for bone regeneration: mechanical reinforcement strategies using nanoparticles and nanofibers.ADMET & DMPK · 2026Review
- Theranostic potential of MXene-based platforms for dual MiRNA targeting in metastatic bladder cancer.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alveolar bone defects pose significant challenges in dentistry. Due to the complexity of alveolar bone anatomy and insufficient repair mechanisms, large bone defects are difficult for the body to heal naturally. Clinical treatment typically involves the use of bone substitute materials. However, current substitutes often suffer from limitations such as insufficient osteoinductivity, rapid degradation, inflammatory responses, and poor mechanical properties. Additionally, the irregular morphology of alveolar bone defects complicates the application of solid bone substitutes, potentially leading to secondary damage at the repair site. Methods: To address these challenges, this study introduces an innovative approach by integrating MXene nanomaterials into Ag-HA/GelMA hydrogels to create an injectable MXene/Ag-HA composite hydrogel. MXene nanomaterials are renowned for their excellent biocompatibility, antibacterial properties, and mechanical strength. Results: The results indicate that the MXene/Ag-HA composite hydrogel exhibits satisfactory mechanical and biological properties. Specifically, it demonstrates excellent antibacterial, antioxidant, and osteogenic activities. Gene expression analysis further reveals that the MXene composite hydrogel promotes osteogenesis by regulating the expression of Dmp1 and Dusp1. Discussion: The findings of this study suggest that the MXene/Ag-HA composite hydrogel is a promising candidate for alveolar bone repair and regeneration. The integration of MXene nanomaterials into the hydrogel enhances its mechanical and biological properties, making it well-suited for the treatment of irregular alveolar bone defects. Furthermore, the study underscores the vast potential of MXene nanomaterials in the biomedical field, hinting at potential applications beyond alveolar bone repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.